Headline results for the second quarter: Revenue: $13.9 billion (forecasts of $13.5 billion), down 4.9% Profit: $2 billion, up from $924 millionNote: All changes are versus the prior-year period unless otherwise statedWhat the company said:CEO Richard Gonzalez said the results "were well ahead of our expectations," adding that the non-Humira business "delivered high single-digit sales growth, in line with our long-term outlook." He added that "we continue to make progress across all stages of our pipeline and based upon the strong momentum of our diversified portfolio, we are once again raising our full year guidance."Other results: Immunology: $6.8 billion, down 5.5% Humira: $4 billion, down 25.2%, Skyrizi: $1.9 billion, up 50.4%, beating analyst expectations of $1.8 billion Rinvoq: $918 million, up 55.1%, topping estimates of $897 million Haematologic oncology: $1.5 billion, down 10.4% Imbruvica: $907 million, down 20.8% Venclexta: $571 million, up 13.1% Neuroscience: $1.9 billion, up 13.6% Botox therapeutic: $748 million, up 10.2% Vraylar: $658 million, up 33.9% Ubrelvy: $196 million, up 5.9% Duodopa: $117 million, down 2.9% Qulipta: $96 million, up >100% Aesthetics: $1.4 billion, up 1% Botox cosmetic: $685 million, down 1.4%, but higher than consensus expectations of $683 million Eye care: $617 million, down 13.9% Restasis: $99 million, down 41.1% Mavyret: $387 million, down 3% Looking ahead:AbbVie said it is raising its earnings outlook for the year to between $10.90 and $11.10 per share, from prior guidance of $10.57 to $10.97 per share. AbbVie noted that its new forecast includes an unfavourable impact of $0.23 per share related to in-process R&D and milestone expenses incurred this year through the second quarter. Analysts projected adjusted profit of $10.85 a share.What analysts said:Analysts said Amgen's Amjevita, the only biosimilar available in the US during the second quarter, has not been able to switch Humira patients as much as estimated since its US market debut in January. The cost of Amjevita, which launched at a 5% and 55% discount on Humira's $6922-per-month price tag, may have contributed to the lower-than-expected uptake, said BMO Capital Markets analyst Evan Seigerman."While Humira biosimilars have entered the market, competitors are priced at parity, potentially resulting in lower erosion than investors expected for the quarter," Seigerman said. He added that Skyrizi and Rinvoq "may continue to provide some assurance" to investors who are questioning how the company will continue to build its revenue base after Humira's loss of market exclusivity. "AbbVie needs to instil confidence that growth from the novel inflammation franchise will drive earnings as Humira turns over with biosimilar entrants," Seigerman said, and while "one quarter of softness isn't great…we're focused on this not becoming a trend."Meanwhile, in response to an analyst question during the company's earnings call, AbbVie also indicated that it was benefiting indirectly from the scramble for weight-loss drugs such as those from Novo Nordisk. AbbVie senior vice president Carrie Strom suggested that some people experiencing "facial hollowing" after rapid weight loss from the drugs are seeking out products from the company's aesthetics business, which makes Botox and dermal fillers. "Anything that gets a consumer engaged in their appearance, including products like Ozempic (semaglutide), are a positive tailwind for the aesthetics business," she said.